The Center for Biotechnology (CFB) is seeking one or more highly‐motivated and experienced BioEntrepreneur(s)‐In‐Residence (B‐EIR) to launch new bioscience ventures in the Long Island region based upon commercially promising biomedical technologies emerging from Stony Brook University. The B‐EIR(s) will be responsible for the identification and evaluation of intellectual property available for license from a pre‐ screened pool of start‐up opportunities. The B‐EIR will engage directly with inventors and CFB senior staff members to determine and outline critical technical milestones to add‐value and mitigate the risk of early stage technology commercialization. The B‐EIR will ultimately select specific biomedical technologies to form the basis of one or more new companies, and will be required to develop detailed commercialization strategies, business plans and investor presentations. The B‐EIR will also (a) negotiate and execute option and/or license agreements with the Office of Technology Licensing and Industry Relations (OTLIR) as may be appropriate, (b) seek and secure capital from both public and private sources, and (c) exit from the B‐EIR program to lead the start‐up company which must be located in the Long Island region.
To help facilitate this process the CFB will:
- Compensate the B‐EIR(s) as an independent consultant during the due diligence and technology development process,
- Provide a modest budget for critical experiments, technology assessment and/or analysis,
- Facilitate access to faculty expertise and core research facilities, business incubator facilities, and business support services as needed,
- Provide senior business development and technology commercialization staff support, as well as the support of MBA, PhD, and JD student teams to assist with market and IP assessments, competitive analyses, and financial modeling,
- Assist with introductions to the Long Island Angel Network (LIAN), Long Island Capital Alliance (LICA), and other Angel and Venture Capital groups.
The successful B‐EIR candidate will possess domain expertise and technical proficiency in the life sciences, as well as business acumen and industry experience, particularly in early‐stage technology commercialization, new venture creation, and fundraising. Advanced degree in a life sciences field, business and/or law are preferred. Compensation and term of engagement dependent upon percentage effort, experience, and the specific start‐up opportunity selected. B‐EIRs will report to the CFB and its Advisory Board (see below). Interested parties should reply to Diane Fabel (firstname.lastname@example.org ), B‐EIR Search Committee, with a statement of interest and resume. Inquiries will be considered through September 30th, or until appropriate candidates are identified.
- Colin Goddard, PhD, Chairman, CEO, Coferon
- Leah Lipsich, PhD, Executive Director, Regeneron Pharmaceuticals
- Glenn D. Prestwich, PhD, Presidential Chair, Medicinal Chemistry, University of Utah Andrew A. Protter, PhD, VP Preclinical Development, Medivation
- Clinton T. Rubin, PhD, Chairman, Biomedical Engineering, Stony Brook University Charles S. Ryan, JD, PhD, Senior VP & Chief Patent Counsel, Forest Laboratories